Corrigendum to “Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial” [Eur. Urol. 86 (2024) 552–562]

IF 25.3 1区医学 Q1 UROLOGY & NEPHROLOGY

European urology Pub Date : 2025-04-08 DOI:10.1016/j.eururo.2025.03.008

Andrew J. Armstrong, Oliver Sartor, Johann de Bono, Kim Chi, Karim Fizazi, Bernd J. Krause, Ken Herrmann, Kambiz Rahbar, Scott T. Tagawa, Fred Saad, Tomasz M. Beer, Jiwen Wu, Osvaldo Mirante, Michael J. Morris

{"title":"Corrigendum to “Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial” [Eur. Urol. 86 (2024) 552–562]","authors":"Andrew J. Armstrong, Oliver Sartor, Johann de Bono, Kim Chi, Karim Fizazi, Bernd J. Krause, Ken Herrmann, Kambiz Rahbar, Scott T. Tagawa, Fred Saad, Tomasz M. Beer, Jiwen Wu, Osvaldo Mirante, Michael J. Morris","doi":"10.1016/j.eururo.2025.03.008","DOIUrl":null,"url":null,"abstract":"The authors regret a minor data error in the reporting of best radiographic responses in Supplementary Table 5 in the Supplementary Material. The percentage of patients with an evaluable response who had progressive disease (PD) in the 'Increase' subgroup for best overall PSA decline from baseline in the 177Lu-PSMA-617 arm should be 31% not 40%. The number of patients with PD (n = 22) and the denominator (n = 71) remain correct. The data in the Table should therefore read as ‘22 (31)’ not ‘22 (40)’. The authors also note that the rows in this Table are slightly misaligned vertically but are presented in the correct order.<figure><img alt=\"\" height=\"479\" src=\"https://ars.els-cdn.com/content/image/1-s2.0-S0302283825001794-fx1.jpg\"/><ol><li>Download: Download high-res image (521KB)</li><li>Download: Download full-size image</li></ol></figure>","PeriodicalId":12223,"journal":{"name":"European urology","volume":"217 1","pages":""},"PeriodicalIF":25.3000,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European urology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.eururo.2025.03.008","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The authors regret a minor data error in the reporting of best radiographic responses in Supplementary Table 5 in the Supplementary Material. The percentage of patients with an evaluable response who had progressive disease (PD) in the 'Increase' subgroup for best overall PSA decline from baseline in the ¹⁷⁷Lu-PSMA-617 arm should be 31% not 40%. The number of patients with PD (n = 22) and the denominator (n = 71) remain correct. The data in the Table should therefore read as ‘22 (31)’ not ‘22 (40)’. The authors also note that the rows in this Table are slightly misaligned vertically but are presented in the correct order.

查看原文本刊更多论文

前列腺特异性抗原水平下降与接受[177Lu]Lu-PSMA-617治疗的转移性钙化耐药前列腺癌患者临床结果的关系》[Eur.

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European urology 医学-泌尿学与肾脏学

CiteScore

43.00

自引率

2.60%

发文量

1753

审稿时长

23 days

期刊介绍： European Urology is a peer-reviewed journal that publishes original articles and reviews on a broad spectrum of urological issues. Covering topics such as oncology, impotence, infertility, pediatrics, lithiasis and endourology, the journal also highlights recent advances in techniques, instrumentation, surgery, and pediatric urology. This comprehensive approach provides readers with an in-depth guide to international developments in urology.